imatinib mesylate All Financial Data in US $ (mln)
Worldwide  
  Overview  
Word Search (Top 10 - by date)
Topline Results From Phase 3 Trial of Sunitinib With Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC)
Pfizer (August 23, 2010)
SPRYCEL® (dasatinib) Receives FDA Priority Review for the Treatment of Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase
Otsuka Pharmaceutical (July 09, 2010)
SPRYCEL® (dasatinib) Receives FDA Priority Review for the Treatment of Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase
Bristol-Myers Squibb (July 09, 2010)
Four-Year Follow-Up Data for SPRYCEL® (dasatinib) Demonstrate 82 Percent Overall Survival in Patients with Chronic Myeloid Leukemia Who Failed Gleevec®*
Otsuka Pharmaceutical (June 07, 2010)
Four-Year Follow-Up Data for SPRYCEL® (dasatinib) Demonstrate 82 Percent Overall Survival in Patients with Chronic Myeloid Leukemia Who Failed Gleevec®1
Bristol-Myers Squibb (June 07, 2010)
SPRYCEL® (dasatinib) Demonstrates Superior Confirmed Complete Cytogenetic Response Rates Compared to Gleevec®* in Study of Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Bristol-Myers Squibb (June 05, 2010)
SPRYCEL® (dasatinib) Demonstrates Superior Confirmed Complete Cytogenetic Response Rates Compared to Gleevec®* in Study of Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Otsuka Pharmaceutical (June 05, 2010)
New Data at ASCO Show Novartis Drug Tasigna® Surpasses Glivec® in Slowing Disease Progression for Newly Diagnosed CML Patients
Novartis (June 04, 2010)
Bristol-Myers Squibb to Present Data on 13 Oncology Compounds During 2010 American Society of Clinical Oncology (ASCO) Annual Meeting
Bristol-Myers Squibb (May 20, 2010)
Pfizer Oncology to Present New Clinical Data From Ten Molecules Across Multiple Tumor Types
Pfizer (May 20, 2010)

Displaying 10 out of a possible 206 unique stories.
Results Sorted By date
Display All Stories

EvaluatePharma® - the premier source for pharma and biotech analysis.

Expert integration of financial and product data across historic and forecast timeframes (1986 to 2016) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status, deals, license revenues and much more.
Summary Generic Name Information
Generic Name: imatinib mesylate
Therapeutic Subcategory:    Other cytostatics
Product Sales Summary 2007/08
Annual Sales WW - Sales Growth per Year (%)
Rank1 Product Company 2007 2008 2008
Generic Name:2 imatinib mesylate       3,050 3,670   +20%  
Note: Shaded Cells3

More Product Information for EvaluatePharma® subscribers

Subscribers see:
  • Sales (historic and forecast to 2016 where available) listed by the product name(s) and reporting company or companies
  • Detailed product information, including sales forecasts listed by the product name(s) and reporting company or companies, indications (approved and in trial)

Register to access more FREE content:

  • 2009 Product Sales analysis
  • Download to Excel
  • Search 2 yrs of company press releases